And the companies need smarter AI. Consider the case of IBM and its marquee Watson system, which was recently the subject of quite the takedown by the Wall Street Journal. It turns out that more than a dozen clients and partners have scaled down or ended their experiments with using Watson in cancer treatment.

《华尔街日报》报道称：“在许多情况下，人工智能工具并未创造出多大的价值。处理某些病历时沃森不够准确，会因为罕见或癌症复发缺乏数据而出错，治疗情况变化的速度明显超过人类培训师更新沃森系统的速度。”

Here’s the relevant bit from that piece: “In many cases, the tools didn’t add much value. In some cases, Watson wasn’t accurate. Watson can be tripped up by a lack of data in rare or recurring cancers, and treatments are evolving faster than Watson’s human trainers can update the system.”